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The quantity of cells with paracrine effects for use in myocardial regeneration therapy is limited. This
study investigated the effects of catheter-based endomyocardial delivery of secretome of 2.5  109
apoptotic peripheral blood mononuclear cells (APOSEC) on porcine chronic post-myocardial infarction
(MI) left ventricular (LV) dysfunction and on gene expression. Closed-chest reperfused MI was induced in
pigs by 90-min occlusion followed by reperfusion of the mid-LAD (day 0). At day 30, animals were
randomized to receive porcine APOSEC (n ¼ 8) or medium solution (control; n ¼ 8) injected intra-
myocardially into the MI border zone using 3D NOGA guidance. At day 60, cardiac MRI with late
enhancement and diagnostic NOGA (myocardial viability) were performed. Gene expression proﬁling of
the infarct core, border zone, and normal myocardium was performed using microarray analysis and
conﬁrmed by quantitative real-time PCR. Injection of APOSEC signiﬁcantly decreased infarct size
(p < 0.05) and improved cardiac index and myocardial viability compared to controls. A trend towards
higher LV ejection fraction was observed in APOSEC vs. controls (45.4  5.9% vs. 37.4  8.9%, p ¼ 0.052).
Transcriptome analysis revealed signiﬁcant downregulation of caspase-1, tumor necrosis factor and other
inﬂammatory genes in APOSEC-affected areas. rtPCR showed higher expression of myogenic factor Mefc2
(p < 0.05) and downregulated caspase genes (p < 0.05) in APOSEC-treated pigs. In conclusion, over-
expression of MEF2c and repression of caspase was related to decreased infarct size and improved
cardiac function in secretome-treated animals. Altered gene expression 1-month post-APOSEC treatment
proved the long-acting effects of cell-free therapy with paracrine factors.
 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY license.ory for Cardiac and Thoracic
urgery, Medical University of
a, Austria. Tel.: þ43 1 40400
00 6977.
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Although great effort has been made to replace infarcted
myocardium with regenerative cells, the current methods have
shownmarginal efﬁcacy in clinical applications [1e5]. According to
the ‘dying stem cell’ hypothesis, regenerative stem cells are already
undergoing apoptosis even as they are being delivered into the
ischemic myocardium [4]. Thus, the best way to attenuate infarc-
tion may be to induce immunomodulatory mechanisms in a
N. Pavo et al. / Biomaterials 35 (2014) 3541e35503542paracrine manner [5e8]. We have shown previously that the
secretome of apoptotic peripheral blood cells (APOSEC), which is
derived from large numbers of easily-obtainable peripheral blood
mononuclear cells (PBMCs), can be used to therapeutically regen-
erate the myocardium after acute ischemic injury [9e12].
The optimal mode of delivering reparative cells or substances
into the ischemic myocardium (i.e. intracoronary or percutaneous
intramyocardial delivery) is still a matter of debate. Intracoronary
delivery of cells increases the risk of temporary occlusion of the
infarct-related artery and requires activemigration of the cells from
the vessel lumen to the injured tissue site [13]. The inherent dis-
advantages of cell therapy include the obvious limitations of the
relatively small number of autologous adult cells that are available
and the relatively large injection volume of the cells, especially for
intramyocardial application [14,15]. Using APOSEC, which contains
a mixture of cytokines and growth factors, might avoid the disad-
vantages of cell-based therapies and be more feasible while also
enhancing therapeutic efﬁciency.
Due to the early death of many regenerative cells when injected
into the necrotic core, intramyocardial regenerative therapies
instead target the infarct border zone, which shows signs of hi-
bernating myocardium. Interestingly, some reports have described
the metabolic, proteomic, and genomic differences between the
infarct core and remote (normal) myocardium, but there is no
genomic information about this special border zone of infarctionFig. 1. Study design. A. Schematic showing how APOSEC is prepared from peripheral blood m
NOGA endocardial mapping and NOGA-guided injection into the border zone of chronic inf
zone of infarction. Color-coded 3D image (upper) were converted to a 2D polar map (below).
border zone of infarction. Normal viable myocardium is colored blue and purple.[16,17]. Furthermore, no studies have investigated the effects of
secretome-based therapies on gene expression in the core and
border zone of myocardial infarction (MI).
We hypothesized that percutaneous intramyocardial delivery of
APOSEC would be safe and effective in a clinically relevant porcine
model of chronic left ventricular (LV) dysfunction after MI. We
further hypothesized that the trophic effect of APOSEC could cause
structural changes, leading to improved hemodynamic function
post-MI via altered gene expression. In our experiments we have
injected APOSEC or placebo locally intramyocardially into the
border zone of infarction using the catheter-based 3D NOGA-
guided intramyocardial application method and investigated the
LV function, infarct size and gene expression of the ischemic injured
myocardium.
2. Materials and methods
2.1. Porcine model of acute MI and APOSEC production
This study used a porcine closed-chest reperfused acute MI model. Domestic
pigs (n ¼ 22) underwent percutaneous 90-min balloon occlusion of the mid-left
anterior descending coronary artery (LAD) followed by reperfusion (Fig. 1 and
Supplementary Materials and Methods). APOSEC was produced from pig PBMCs
(Supplementary Materials and Methods). Animal investigations were carried out in
accordance with the “Position of the American Heart Association on Research Ani-
mal Use,” as adopted by the AHA on November 11, 1984. The study was approved by
the Ethics Committee on Animal Experimentation at the University of Kaposvar,
Hungary.ononuclear cells (PBMCs). B. Study design. C. 3D views of the left ventricle derived by
arction. Brown dots mark the locations of the intramyocardial injections in the border
Red represents non-viable infarcted myocardium, while green and yellow indicated the
N. Pavo et al. / Biomaterials 35 (2014) 3541e3550 35432.2. Percutaneous intramyocardial delivery of APOSEC or medium solution using 3D
NOGA guidance
Onemonth after MI (day 30; development of scar and LV remodeling; Fig. 1), the
animals were sedated, intubated, and the patency of the infarct-related artery was
conﬁrmed by coronary angiography. LV hemodynamic parameters were measured
via pigtail catheters. NOGA endocardial mapping was performed using a percuta-
neous NOGA Star catheter (Cordis, Johnson & Johnson, Miami Lakes, FL, USA) as
described previously [18]. After creation of the 3D shape of the LV infarction, the
diagnostic NOGA Star catheter was replaced by a NOGA MyoStar injection catheter
(Cordis, Johnson & Johnson). The pigs were randomized to receive either APOSEC
(derived from 2.5  109 PBMCs, resuspended in 4 ml physiologic saline, 300-ml al-
iquots) or medium as a control (resuspended lyophilized Cell Growth medium) in
11  1 locations of the border zone of infarction using 3D NOGA-guided percuta-
neous intramyocardial delivery. The animals were allowed to recover. At 60 days
post-infarction (30 days post-injection), control coronary angiography and NOGA
endocardial mappingwere performedwhile the pigs were under general anesthesia.
2.3. Cardiac magnetic resonance imaging (MRI)
CardiacMRI with late enhancement (LE) was performed 3 days and 60 days after
the reperfused acute MI procedure using a 1.5-T clinical scanner (Avanto, Siemens,
Erlangen, Germany) with a phased-array coil and a vector ECG system
(Supplementary Materials and Methods). The LV end-diastolic (EDV) and end-
systolic (ESV) volumes, ejection fraction (EF), and infarct size were measured
(Supplemental Materials and Methods) [19].
2.4. LV hemodynamic measurements
LV hemodynamic measurements were performed via pigtail catheter and
included systolic aortic pressure, LV systolic and end-diastolic pressures (EDP), LV
contractility expressed as dP/dt and dP/dt/P, and LV end-diastolic stiffness (LV EDP/
EDV).
2.5. Myocardial viability, infarct transmurality and regional functional assessment
by NOGA
Using the 12-segment polar map analysis principles, the mean unipolar, bipolar,
and local linear shortening values (UPV, BiP, and LLS, respectively) of the injected
areas were calculated and reported as mV or %, respectively.
2.6. Histology
The hearts were explanted at day 60 and sliced, and representative specimens of
normal tissue and of the border zone and infarcted areas were ﬁxed in 10% neutral
buffered formalin, embedded in parafﬁn, sectioned, and stained for hematoxylin-
eosin, angiogenic marker of CD31 and stem cell factor CD117 (Supplemental
Materials and Methods).
2.7. Gene expression analysis using RNA microarrays and real-time PCR (rtPCR)
Tissue samples for RNA extraction were obtained directly from the infarct core,
border zone, and remote myocardium and stored in RNAlater (Qiagen, Germany)
at 20 C. Total RNA was isolated from tissue samples using the RNeasy Microarray
Tissue Mini Kit (Qiagen, Germany). RNA quality was checked on RNA Nano chips
using the Agilent 2100 Bioanalyzer platform (Agilent Technologies).
2.7.1. RNA microarrays
Microarray gene analysis was performed by Miltenyi (Miltenyi Biotec GmbH,
Germany) (Supplemental Materials and Methods). The ﬂuorescence signals of the
hybridized Agilent Microarrays were measured using Agilent’s Microarray Scanner
System (Agilent Technologies) and analyzed using Agilent Feature Extraction Soft-
ware (FES).
Raw hybridization values were loaded into R (GNU R) using the R-package
limma (v3.14.4) [20,21]. Microarray data have been uploaded to the Gene Expression
Omnibus database (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc¼GSE47397). Biological interpretation of signiﬁcant gene lists was performed
using the Database for Annotation, Visualization and Integrated Discovery (DAVID)
v6 [22]. Data were reported in annotational clusters or as single gene expression,
heat maps, and Venn diagrams.
2.7.2. rtPCR of selected genes
The mRNA of myocardial probes of all 3 regions from both groups of pigs was
reverse transcribed to cDNA (Qiagen, Germany) and expression was quantiﬁed by
rtPCR (Applied Biosystems 7500 Real-Time PCR System, Life Technologies, USA). The
primers for the target sequences were designed using Primer3 software (http://
primer3.wi.mit.edu/primer3web_help.htm; Microsynth, Switzerland)
(Supplemental Table 1). The expression rates of the target genes were normalized to
the geometric means of the housekeeping genes GAPDH, HPRT1, and PPIA, which
were selected as endogenous controls due to their stable expression. The relative
gene expression level was calculated using the DCt method (i.e. expression levelrelative to an endogenous control). The expression changes were calculated relative
to expression levels in the normal myocardium of the same animal.
2.8. Statistics
Continuousdataof the twogroupsofpigsare reportedasmean standarddeviation.
Differences between the groups were tested using the Student’s t test for continuous
variables and thec2 test for categorical variables. Adifferencewas considered statistically
signiﬁcant at p < 0.05. Data analyses and interpretations were performed by an experi-
enced observerwhowas blinded to the randomization and to all study results. Statistical
analysis was performed using SPSS 18.0 (SPSS Inc, USA) software.
For gene array analysis, to test for all comparisons (i.e. differences between re-
gions of interest: normal, border, and infarct and APOSEC vs. control) a linear model
for each genewas ﬁtted and the estimated coefﬁcients and standard errors for these
contrasts were computed. Subsequently, moderated t-statistics, moderated F-sta-
tistics, and the log-odds of differential expression were calculated by empirical
Bayes shrinkage of the standard errors towards a common value. False discovery
rates (FDR) below 5% were considered statistically signiﬁcant for each comparison.
Higher FDR cut-offs were used for some contrasts, especially for the use of the gene
lists for biological interpretation. Unsupervised hierarchical clustering was per-
formedwith the Euclidean distance as the distance function and theWard algorithm
in R, using centered and scaled log2 expression values. Principal Component Anal-
ysis (PCA) was also performed for centered and scaled values.
3. Results
3.1. Effect of APOSEC on infarct size and hemodynamics
Six pigs died during the reperfused MI procedure (n ¼ 5) or 2
days later (n ¼ 1). The remaining 16 pigs were randomized to the
APOSEC group (n ¼ 8) or to the control group (n ¼ 8).
Figs. 2 and 3 show the 3-day and ﬁnal MRI data. Compared to
control animals, the APOSEC-treated animals had signiﬁcantly
smaller infarcts (13.92  1.34% vs. 21.58  2.09%, p < 0.05) and a
signiﬁcantly higher cardiac index (4.40  3.94 l/min/m2 vs.
3.07  2.35 l/min/m2, p < 0.05). There was also a trend towards a
higher EF (45.4  5.9% vs. 37.4  8.0%, p ¼ 0.052) and signiﬁcant
changes in LV EF from baseline to follow-up (FUP) in the APOSEC-
treated vs. control animals. The area at risk as measured by MRI
at day 3 was similar in the two groups (46  9% vs. 45  10% of the
entire LV myocardium).
The baseline, pre-injection, and post-injection hemodynamic
data was not different between the groups (data not shown).
Signiﬁcantly lower EDP and end-diastolic stiffness was measured in
the APOSEC group at the ﬁnal FUP (Fig. 3). Infarct transmurality, as
assessed by MRI and NOGA bipolar maps, showed smaller trans-
mural infarctions in the APOSEC-treated pigs (Fig. 2). The APOSEC-
treated animals had signiﬁcantly higher UPV and BiP values for the
treated area with a trend towards higher LLS (Fig. 4).
3.2. Angiogenesis and homing of endogenous c-kit positive cells in
the border zone of experimental MI
There was a signiﬁcant increase in the number of CD31þ cells in
the APOSEC group in the border zone of infarction, indicating
enhanced angiogenesis (Fig. 5). The CD31þ cell density per DAPI
positive cells in the infarct and border zone were 15.3  1.9% vs.
12.6  4.5% and 19.9  1.8% vs. 11.3  3.2% in the APOSEC vs. con-
trols. Signiﬁcantly (p < 0.05) higher numbers of CD117þ cells were
found in infarct core (2.0  0.9% vs. 0.6  0.7%) and border area
(3.0  1.4% vs. 0.9  0.8%) in APOSEC-pigs suggesting enhanced
accumulation of endogenous cardiac stem cells as compared with
medium-treated animals.
3.3. Gene expression differences between APOSEC- and medium-
treated animals
Differential gene expression of infarcted, border zone, and
remotemyocardium in the chronic failing hearts before treatment is
Fig. 2. Left ventricular function and infarct transmurality assessed by MRI and NOGA. A. Short axis views of follow-up (FUP) late enhancement (LE) magnetic resonance images
show end-diastolic (EDV) and end-systolic (ESV) contours with LE 30 days after percutaneous intramyocardial injection of APOSEC or medium solution. Note the reduced ventricular
volumes and infarct area in an APOSEC-treated pig. B. Bull’s eye plots of LE-MRI data demonstrating treatment effects in representative APOSEC-treated (top row) and medium-
treated (control) pigs (bottom row). Note that segmental infarct transmurality is reduced in the FUP images of an APOSEC-treated pig, while slight enlargement of the infarct area is
seen in a medium solution-treated pig. The following segments are affected: middle anterior, middle anteroseptal, apical anterior, and apical septal. Left and middle panels:
segmental infarct transmurality in 3-day and 30 days after injection (FUP, day-60) MR images. Transmurality was measured as the percentage of the LE area (i.e. the scar) relative to
the volume of the corresponding myocardial segment. Right panels: treatment effects as visualized by differences between FUP and day-3 segmental measurements. Positive values
refer to growing segmental infarct transmurality (red) while negative values indicate reduced infarct transmurality (blue). C. Bull’s eye plots of NOGA bipolar (transmurality) maps
at baseline (injection) and FUP corresponding to the MRI polar plots (B) in the same APOSEC- and control pigs. Red represents greater infarct transmurality.
N. Pavo et al. / Biomaterials 35 (2014) 3541e35503544shown in the Supplemental Results. PCA and hierarchical clustering
of the gene expression patterns of the corresponding myocardial
areas in APOSEC- andmedium-treated animals revealed 10 genes in
the infarct core and 23 genes in the globally treated areas (infarct
core andborder zone) that showed signiﬁcantly differentexpression
compared to remote myocardium (Fig. 6, Table 1). Systematic and
integrative gene analysis using DAVID Bioinformatics Resources
identiﬁed and classiﬁed only a portion of the signiﬁcantly up and
downregulated genes (11 of 23 genes, 47.8%). Due to the expression
of single genes in several pathways, these genes could not be clas-
siﬁed into unique clusters. There was signiﬁcant downregulation of
apoptosis-, inﬂammation-, and lipid metabolism-associated genes.
This included repression of caspase-1 (apoptosis-related cysteine
peptidase and interleukin 1-beta-convertase), tumor necrosis factor
alpha (TNF-alpha), stromal derived factor (SDF)2-like protein 1
(endoplasmic reticulum stress-inducible gene), arachidonate 15-
lipoxygenase (lipid metabolism), uroplakin 1B (coding a trans-
membrane protein), claudin 3 (tight junction protein), and other
genes that were not characterized further.
Using less-stringent criteria (FDR <10%), additional 53 genes
were detected that showed different expression levels in the
APOSEC group vs. the control group. Of these, 24 genes wereidentiﬁed by the functional annotation analysis (Table 1). Six of the
24 genes were overexpressed, while 18 were repressed.
The APOSEC-affected myocardial area showed upregulation of
insulin-like growth factor (an angiogenic growth factor), Kruppel-
like factor (a regulator of vascular tone and homeostasis and an
anti-atherogenic), myozenin (a gamma-ﬁlamin and alpha-actinin-
binding protein in skeletal muscles), and a gene similar to glycer-
onephosphate O-acyltransferase (thought to protect cells from
oxidative stress). In contrast, some of the downregulated genes
belonged to the inﬂammatory and immune system superfamily:
killer cell lectin-like receptor subfamily K, cystatin F, ectonucleoside
triphosphate diphosphohydrolase 1, CD2, complement component
1 q subcomponent, A-chain, C-X-C motif ligand 9 and 10, C-type
lectin domain family 5, member A, CD247, and beta-2 micro-
globulin. Other downregulated genes included some involved in
lipid metabolism (a scavenger receptor for phosphatidylserine and
oxidized low density lipoprotein), a histocompatibility antigen
(MHC class II DR-alpha), a structural matrix protein (ameloblastin),
and other less well characterized genes (suppression-inducing
transmembrane adapter 1).
If FDR <20% was used (data available at the GEO homepage),
additional annotated overexpressed genes in the border area of
Fig. 3. MRI results. Ejection fraction (EF) at day 3 (BASE) and at day 60 (follow-up; FUP) showing a signiﬁcant increase in EF at FUP in the APOSEC-treated pigs (n ¼ 8) compared to
the control pigs (n ¼ 8). The APOSEC-treated pigs showed signiﬁcantly smaller infarct size and better cardiac indexes. There was signiﬁcantly lower end-diastolic pressure and end-
diastolic stiffness in the APOSEC-treated group. *p < 0.05.
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686 genes). These clusters included genes involved in purine
metabolism (phosphodiesterase 3A, 4A, and 4B, pyruvate kinase),
in the cell cycle (e.g. ﬁzzy/cell division cycle 20 related 1), in the
calcium signaling pathway (adrenergic beta-1 receptor, nitric
oxide synthase 2, inducible, calmodulin), and in regulation of the
actin cytoskeleton (ﬁbronectin receptor, vinculin/cell adhesion
related gene/). The clusters also included other cardiac-related
genes, such as myocardin (important for cardiomyocyte survival
and maintenance), GATA-binding protein 4 (transcription factor
needed for normal heart development), and adrenergic beta-1
receptor. The main clusters of downregulated genes in the
border zone of the APOSEC-treated animals included genes
responsible for toll-like receptor pathways (CD40 molecule, CD86
molecule, chemokine ligands, interleukin-1 receptor-associated
kinase 4, and toll-like receptor 3 and 7, which are responsible for
the innate immune response and mediation of ischemic/reper-
fusion injury), and genes involved in cardiomyopathy (trans-
forming growth factor beta).
3.4. rtPCR
rtPCR analysis of mRNA expression in the border zone of
infarction in the APOSEC-treated animals conﬁrmed that there was
signiﬁcant overexpression of the cardiac myogenesis and vascular
development gene, myocyte-speciﬁc enhancer factor 2C (MEF2c),
and repression of the apoptosis regulator caspase-3 (Fig. 6). In the
border zone, there was a trend towards higher expression (p < 0.1)
of angiogenic regulatory factor hypoxia-inducible factor 1-alpha
and transcription factor GATA-4 in the APOSEC group comparedwith the control group. There were no signiﬁcant differences be-
tween the groups in terms of the expressions of genes involved in
stem cell homing (CXCR12), the transcription factor myogenin, and
the extracellular matrix proteins matrix metalloproteinase-9 and
transforming growth factor beta.
4. Discussion
Here we demonstrated that 3D NOGA-guided injection of
APOSEC is safe, feasible, and effective. APOSEC injection was asso-
ciated with an enhanced vascular density and homing of c-kitþ
endogenous stem cells in the peri-infarct and infarcted area, with a
reduction of infarct size, and with a signiﬁcant increase in LV EF
contractile function. Gene proﬁling analysis of the APOSEC-treated
myocardial areas revealed that there was downregulation of in-
ﬂammatory and apoptotic genes. Post-hoc validation of gene
expression by rtPCR showed higher expression levels of myogenic
factor and Mefc2 and robust downregulation of apoptosis regulator
caspase-3.
We previously showed that similar to the secretome of
mesenchymal stem cells (MSCs) [23], APOSEC contains anti-
apoptotic and regenerative factors that promote angiogenesis and
myocardial repair [11,12]. In contrast to MSCs, PBMCs contain
different types of mononuclear cells. However, one big advantage of
PBMCs is that the available autologous cells are numerous. Even if
ex vivo cell culture expansion of MSCs might provide sufﬁcient
quantities of secretome, the biological characteristics of the MSC
secretome depend on the number of passage of the cells with
possibility to chromosome variability after passage 4, and on the
cell donor, making it difﬁcult to standardize secretome production
Fig. 4. NOGA results and representative NOGA images. A. Baseline (BASE) and follow-up (FUP) unipolar voltage (an index of myocardial viability) of the injected area of APOSEC- and
medium-treated (control) pigs. At FUP (day-60), the APOSEC group had signiﬁcantly higher unipolar voltage values (left) and bipolar voltage (index of infarct transmurality) values.
There were trends towards higher local linear shortening voltage values (an index of segmental wall motion) at FUP. B. Representative NOGA images show the injection points
around the infarcted area in APOSEC- and medium-treated pigs. The infarcted area is visibly smaller at FUP in the APOSEC-pigs, indicating that ventricular remodeling was reduced
in these animals. Color coding is as deﬁned in Fig. 1.
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erative factors did not exert effects that were similar to those of the
naturally derived secretome [23].
Our experiments investigated changes in the gene expression
proﬁle of the host tissue (ischemically injured myocardial cells)
after direct contact with the injected mixture of paracrine factors
(APOSEC). Even if reparative cells in cell-based therapies that are
delivered to the ischemic area produce numerous signaling mole-
cules, such as matrix proteins and anti-inﬂammatory and angio-
genic substances, the host tissue response is the crucial factor in
myocardial tissue regeneration.
Changes in gene expression in ischemic cells depend on the
severity of the injury. Interestingly, APOSEC mainly caused gene
silencing in the pro-inﬂammatory cascade along with, to a lesser
extent, some gene induction. However, it is important to note thatalmost half of the downregulated genes, and none of the upregu-
lated genes, had currently known functions. These latter genes
might belong to metabolic, angiogenic, or myogenic functional
clusters that cause synergistic regenerative processes as demon-
strated by infarct size reduction and prevention of ventricular
remodeling.
4.1. APOSEC induces long-lasting differences in gene expression
Although the studies were exploratory, previous analyses of the
gene expression proﬁles of chronically infarcted, reperfused, and
remodeled ischemic myocardium identiﬁed functional uni- or
bimodal genes with known functions [24e30]. The published data,
which are mostly from studies conducted in rodent MI models, are
heterogeneous in terms of the number and type of differentially-
Fig. 5. Angiogenic effect of APOSEC. AeD. H&E stained porcine myocardium 60 days after induction of myocardial infarction and treated with intramyocardial injection of APOSEC
or medium (infarct core A and C, /40 magnification/, and border zone of infarction B and D, /10 magniﬁcation/, respectively). EeH. Immunoﬂuorescence CD31þ staining of the
infarct core (E and G) and border areas (F and H) of an APOSEC or medium-treated pig, respectively. Red indicates CD31þ cells, counterstaining with DAPI. IeL. CD117 (c-kitþ)
immunoﬂuorescence staining of the infarct core (I and K) and border areas (J and L) of an APOSEC or medium-treated pig, respectively. Green color represents CD117þ cells,
counterstained with DAPI. M and N. APOSEC-treated pigs show a higher density of CD31þ and CD117þ cells both in infarct core and border areas, indicating enhanced level of
microvascularization and homing of endogenous c-kitþ cardiac stem cells (*p < 0.05).
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expression proﬁles in closed-chest reperfused MI and also the ﬁrst
report to describe molecular biological changes in remote and
infarcted myocardium and in the border zone of infarction
(Supplemental Discussion).
Locally injected APOSEC contains paracrine factors proven to be
anti-inﬂammatory, leading to repressionof activepro-inﬂammatory
genes, such as genes coding for TNF-alpha, SDF2-like protein 1, and
caspase-1. However, several genes that showed signiﬁcantly
changed expression are currently not assigned to known function.
The expansion of the FDR <5% cut-off to a FDR <10% cut-off gave
more information about changes in gene expression in APOSEC-
treated areas. Speciﬁcally, this less-stringent cut-off identiﬁed
several relevant genes with altered expression. There was upregu-
lation of angiogenic factors andother vascular tone andhomeostasis
regulators and repression of pro-inﬂammatory genes such as com-
plement components and histocompatibility antigens.
4.2. Comparison with literature data
In contrast to the large animal model of reperfused MI used
here, Jameel et al. surgically ligated the ﬁrst and second diagonal
branches of LAD of mini-swine and immediately injected 50million
bone marrow-derived multipotent progenitor cells [31]. This sur-
gical cell transplantation resulted in a marked improvement in EF
(51.2% vs. 35.7%) and in a decrease in infarct size (4.6% vs. 8.6%) at
the 4-month FUP in treated vs. control groups, respectively,without engraftment of the cells. Gene expression analysis revealed
41 downregulated and 11 upregulated genes in the cell trans-
plantation group; the authors attributed these changes to the
paracrine effects of the injected cells. There was also down-
regulation of genes in the inﬂammatory pathway, similar to what
was seen in our experiments. The differences between the gene
expression pathways identiﬁed in the two studies may due to the
use of different MI models and treatments as well as to the pres-
ence of different paracrine mediators.
Similar to the MSC secretome [23], the secretome of apoptotic
PBMCs (i.e. APOSEC) has the potential to block apoptosis and local
inﬂammation, enhancing neoangiogenesis and limiting infarct
expansion and remodeling. Through overexpression of regulatory
genes at the FDR <10% level, such as Kruppel-like factor and
myozenin, it is possible that APOSEC acts to restore vascular and
muscle homeostasis. We did not see changes in any genes that are
known to contribute to endogenous regeneration via the mobili-
zation and homing of cardiac or bone marrow stem cells, such as
genes coding for SDF-1 or for chemotactic cytokines. There is also
the question of the importance of isolated gene expression i.e.
expression of genes that are not functionally related to each other
or that are in different pathways. However, small changes in the
function of a key gene can act as a signal that triggers a biologically
relevant effect.
rtPCR of selected genes conﬁrmed the signiﬁcant repression of
the apoptosis regulator caspase-3. The increase in expression of
hypoxia-inducible factor 1-alpha and GATA-4 in the border zone of
Fig. 6. Gene array analysis of differential expression of gene clusters in APOSEC-treated and medium-treated pigs in the infarct core and treated region (infarct core and border zone). A. Comparison of genes with signiﬁcantly different
expression levels [false discovery rate (FDR) 5%] in infarct (left) and treated regions (right; infarct core and border zone) of APOSEC- and medium-treated pigs (clustered and reported as a heat map). Name of genes: 1 ¼ similar to
LOC513955 protein; 2 ¼ CD209 molecule; 3 ¼ n.i.; 4 ¼ claudin 3; 5 ¼ n.i.; 6 ¼ similar to trichohyalin; 7 ¼ arachidonate 15-lipoxygenase; 8 ¼ epididymal secretory protein; 9 ¼ CD209 molecule; 10 ¼ uroplakin 1B; 11 ¼ n.i.; 12 ¼ n.i.; 13
¼ n.i.; 14 ¼ similar to trichohyalin; 15 ¼ similar to Uncharacterized protein CXorf21 homolog; 16 ¼ n.i.; 17 ¼ caspase 1. apoptosis-related cysteine peptidase (interleukin 1. beta. convertase); 18 ¼ n.i.; 19 ¼ n.i.; 20 ¼ tumor necrosis factor
(ligand) superfamily member 13b; 21 ¼ similar to Stromal cell-derived factor 2-like protein 1 precursor (SDF2-like protein 1) (PWP1-interacting protein 8); 22 ¼ similar to LOC513955 protein; 23 ¼ arachidonate 15-lipoxygenase; 24 ¼
n.i.; 25 ¼ epididymal secretory protein; 26 ¼ uroplakin 1B; 27 ¼ n.i.; 28 ¼ n.i.; 29 ¼ n.i.; 30 ¼ n.i.; 31 ¼ claudin 3; 32 ¼ similar to Protein S100-A2 (S100 calcium-binding protein A2) (Protein S-100L); 33 ¼ n.i. n.i. ¼ not identiﬁed genes.
B. Results of real-time PCR analysis of the expression of selected genes in APOSEC- and medium-treated pigs: HIF1-a: hypoxia-inducible factor 1-a; MMP-9: matrix metalloproteinase-9, CXCL12: chemokine (C_X_C motif) ligand-12;
MEF2c: myocyte-speciﬁc enhancer factor 2c; MYOG: myogenin; GATA-4: zinc ﬁnger transcription factor that binds to the DNA sequence “GATA”-4; TGF-beta3: transforming growth factor-beta3. Y axis: expression level normalized to
gene expression of the normal myocardium. Each group: n ¼ 8. *p < 0.05.
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Table 1
Up and downregulated genes of the infarct core and combined treated (infarct core and border zone) areas in the APOSEC-treated animals.
Systematic name Log fold changes Adjusted P value Name of gene Regulation in
APOSEC group
Infarct core FDR5%
NM_001129972 1.426 0.029 CD209 molecule Down
NM_213931 3.367 0.038 Arachidonate 15-lipoxygenase Down
ENSSSCT00000010283 0.675 <0.001 Similar to LOC513955 protein Down
NM_001160075 0.798 <0.001 Claudin 3 Down
ENSSSCT00000013027 2.047 0.005 n.i. Down
NM_001123212 1.081 0.001 Uroplakin 1B Down
TC533994 1.573 0.043 n.i. Down
ENSSSCT00000008105 1.249 0.016 Epididymal secretory protein Down
XM_001927650 0.847 0.002 Similar to trichohyalin Down
Combined treated areas FDR5%
NM_214162 1.887 0.029 Caspase 1-apoptosis-related cysteine peptidase (interleukin 1-beta-convertase) Down
NM_001097498 0.753 0.015 Tumor necrosis factor (ligand) superfamily member 13b Down
ENSSSCT00000010283 0.815 0.003 Similar to LOC513955 protein Down
NM_001160075 0.949 0.005 Claudin 3 Down
ENSSSCT00000013346 1.18 0.007 Similar to uncharacterized protein CXorf21 homolog Down
NM_001123212 1.287 0.01 Uroplakin 1B Down
ENSSSCT00000011046 1.623 0.014 Similar to stromal cell-derived factor 2-like protein 1 precursor (SDF2-like protein 1)
(PWP1-interacting protein 8)
Down
ENSSSCT00000007208 2.936 0.015 Similar to Protein S100-A2 (S100 calcium-binding protein A2) (Protein S-100L) Down
ENSSSCT00000008105 1.249 0.016 Epididymal secretory protein Down
XM_001927650 0.908 0.022 Similar to trichohyalin Down
NM_213931 3.367 0.038 Arachidonate 15-lipoxygenase Down
TC520240 1.61 0.047 n.i. Down
ENSSSCT00000013027 2.617 0.013 n.i. Down
AK233548 1.097 0.015 n.i. Down
ENSSSCT00000011046 1.297 0.015 n.i. Down
AK230687 2.509 0.015 n.i. Down
ENSSSCT00000011934 1.895 0.016 n.i. Down
A_72_P409998 0.929 0.007 n.i. Up
TC601625 1.154 0.013 n.i. Up
TC591961 0.592 0.015 n.i. Up
TC540937 2.522 0.015 n.i. Up
TC526711 3.032 0.029 n.i. Up
AK232497 2.857 0.04 n.i. Up
Combined treated areas FDR between 5% and 10%
NM_214037 1.42 0.093 Ameloblastin Down
DQ845172 1.5 0.097 Beta-2-microglobulin Down
NM_213990 1.51 0.093 C-type lectin domain family 5, member A Down
NM_213776 1.26 0.093 CD2 molecule Down
NM_214155 1.18 0.093 CD247 molecule Down
NM_001008691 3.35 0.093 Chemokine (C-X-C motif) ligand 10 Down
NM_001114289 3.97 0.097 Chemokine (C-X-C motif) ligand 9 Down
NM_001003924 1.89 0.093 Complement component 1, q subcomponent, A-chain Down
NM_214153 1.32 0.093 Ectonucleoside triphosphate diphosphohydrolase 1 Down
NM_214000 0.95 0.008 Haptoglobin Down
NM_213813 2.46 0.063 Killer cell lectin-like receptor subfamily K, member 1 Down
NM_001097415 0.81 0.089 Lymphocyte antigen 86 Down
NM_001113706 1.64 0.093 MHC class II DR-alpha Down
NM_213811 2.36 0.076 Scavenger receptor for phosphatidylserine and oxidized low density lipoprotein Down
ENSSSCT00000007803 1.72 0.081 Similar to cystatin F Down
AK232017 2.63 0.097 Similar to signaling threshold-regulating transmembrane adapter 1 precursor
(suppression-inducing transmembrane adapter 1) (SHP2-interacting
transmembrane adapter protein) (gp30/40)
Down
NM_001001632 1.45 0.08 Tropomyosin 3 Down
NM_213883 3.05 0.063 Insulin-like growth factor 2 (somatomedin A) Up
NM_001134346 1.41 0.093 Kruppel-like factor 11 Up
NM_001025222 1.39 0.097 Myozenin 1 Up
ENSSSCT00000007708 0.92 0.093 Prion protein Up
ENSSSCT00000011141 1.01 0.093 Similar to glyceronephosphate O-acyltransferase Up
AY609888 0.67 0.081 Similar to NAD(P) dependent steroid dehydrogenase-like Up
AY609888 0.78 0.097 Similar to NAD(P) dependent steroid dehydrogenase-like Up
Further not identiﬁed genes at FDR 5-10%: downregulated: EW261758, NM_001243319, AK397775, DN121339, TC533994, TC544302, L21161, ENSSSCT00000000690,
NM_001161643, ENSSSCT00000005170, A_72_P418159, A_72_P418159, AK394244, TC594134, TC569821, CK451290, TC608152, AK230519, TC591665, TC544851,
NM_001256770, TC555560, ENSSSCT00000017072, A_72_P773461, TC611786, AK239173; and upregulated in APOSEC-treated animals: TC543654, TC614889, BX923234,
AK349090.
FDR: false discovery rate, n.i.: not identiﬁed genes.
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treated animals. MEF2c expression was induced and showed sig-
niﬁcant overexpression in the gene arraywhen FDR<20%was used.
4.3. Limitations
Control animals received local intramyocardial injections of
medium solution, therefore the gene expression might be different
from that in non-treated infarcted animals. Therefore it is not
appropriate to conduct a direct comparison of our “medium-solu-
tion-treated” control group with literature data that describe gene
patterns in rodent ischemic/reperfusion hearts [30] or in rodent or
pig chronic ischemia/infarction models using placebo, sham oper-
ation or no treatment in control animals [25e28,31].
Macroscopic identiﬁcation of the real border zone of the
infarction at day 60 that corresponds to the injected area at day 30
is crucial for obtaining valuable information from the experiments.
In this study, localizing the LAD segment close to the origin of the
second diagonal branch where the occlusion was made previously
and identifying the margin of the infarcted area proved technically
feasible. In addition, the differences in the gene expression proﬁles
in the normal, border, and infarct areas conﬁrmed that these areas
were sampled correctly.
5. Conclusions
APOSEC attenuates chronic myocardial ischemia-induced ven-
tricular remodeling in a clinically relevant large animal model.
Speciﬁcally, APOSEC induced long-lasting differences in gene
expression that led to silencing of genes involved in apoptosis and
inﬂammation. The gene proﬁling results identiﬁed genes that
represent targets for anti-remodeling and anti-ischemic therapy.
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